Living Cell Technologies Limited (LVCLF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 2.2 Million AUD | 3.47% |
| 2023 | 2.12 Million AUD | -10.43% |
| 2022 | 2.37 Million AUD | 4.08% |
| 2021 | 2.28 Million AUD | -27.87% |
| 2020 | 3.16 Million AUD | -24.12% |
| 2019 | 4.17 Million AUD | -5.01% |
| 2018 | 4.39 Million AUD | -18.18% |
| 2017 | 5.36 Million AUD | 32.66% |
| 2016 | 4.04 Million AUD | 21.88% |
| 2015 | 3.32 Million AUD | 50.84% |
| 2014 | 2.2 Million AUD | 32.2% |
| 2013 | 1.66 Million AUD | -63.33% |
| 2012 | 4.54 Million AUD | -50.06% |
| 2011 | 9.09 Million AUD | 20.12% |
| 2010 | 7.57 Million AUD | -5.31% |
| 2009 | 7.99 Million AUD | 13.15% |
| 2008 | 7.06 Million AUD | 1.7% |
| 2007 | 6.94 Million AUD | -2.29% |
| 2006 | 7.1 Million AUD | 23.33% |
| 2005 | 5.76 Million AUD | 454.05% |
| 2004 | 1.04 Million AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 FY | 2.2 Million AUD | 3.37% |
| 2024 Q2 | 1.5 Million AUD | 99.94% |
| 2024 Q3 | 376.09 Thousand AUD | -74.95% |
| 2024 Q4 | 376.09 Thousand AUD | 0.0% |
| 2024 Q1 | 750.83 Thousand AUD | -8.3% |
| 2023 Q1 | 657.5 Thousand AUD | -47.61% |
| 2023 Q3 | 417.33 Thousand AUD | -68.16% |
| 2023 Q4 | 818.76 Thousand AUD | 96.19% |
| 2023 Q2 | 1.31 Million AUD | 99.35% |
| 2023 FY | 2.12 Million AUD | -10.43% |
| 2022 Q1 | 556.77 Thousand AUD | -50.24% |
| 2022 FY | 2.37 Million AUD | 4.08% |
| 2022 Q2 | 1.12 Million AUD | 101.21% |
| 2022 Q4 | 1.25 Million AUD | 98.91% |
| 2022 Q3 | 630.94 Thousand AUD | -43.68% |
| 2021 FY | 2.28 Million AUD | -27.87% |
| 2021 Q2 | 1.15 Million AUD | 339.58% |
| 2021 Q1 | 263.87 Thousand AUD | -81.32% |
| 2021 Q3 | 822.94 Thousand AUD | -29.05% |
| 2021 Q4 | 1.11 Million AUD | 35.97% |
| 2020 FY | 3.16 Million AUD | -24.12% |
| 2020 Q3 | 1.12 Million AUD | -35.07% |
| 2020 Q2 | 1.73 Million AUD | 875.88% |
| 2020 Q4 | 1.41 Million AUD | 25.3% |
| 2020 Q1 | 177.92 Thousand AUD | -84.83% |
| 2019 FY | 4.17 Million AUD | -5.01% |
| 2019 Q1 | 950.44 Thousand AUD | 80.2% |
| 2019 Q4 | 1.17 Million AUD | 0.0% |
| 2019 Q2 | 1.86 Million AUD | 96.72% |
| 2019 Q3 | 1.17 Million AUD | -37.25% |
| 2018 Q1 | 1.19 Million AUD | -10.66% |
| 2018 FY | 4.39 Million AUD | -18.18% |
| 2018 Q4 | 527.43 Thousand AUD | 0.0% |
| 2018 Q3 | 527.43 Thousand AUD | -56.02% |
| 2018 Q2 | 1.19 Million AUD | 0.0% |
| 2017 Q3 | 1.34 Million AUD | -0.61% |
| 2017 FY | 5.36 Million AUD | 32.66% |
| 2017 Q4 | 1.34 Million AUD | 0.0% |
| 2017 Q1 | 1.35 Million AUD | 25.66% |
| 2017 Q2 | 1.35 Million AUD | -0.0% |
| 2016 Q2 | 892.6 Thousand AUD | -0.0% |
| 2016 FY | 4.04 Million AUD | 21.88% |
| 2016 Q4 | 1.07 Million AUD | 0.0% |
| 2016 Q3 | 1.07 Million AUD | 20.4% |
| 2016 Q1 | 892.6 Thousand AUD | -63.21% |
| 2015 Q4 | 2.42 Million AUD | 0.0% |
| 2015 FY | 3.32 Million AUD | 50.84% |
| 2015 Q2 | 1.32 Million AUD | 0.0% |
| 2015 Q3 | 2.42 Million AUD | 83.37% |
| 2015 Q1 | 1.32 Million AUD | -36.8% |
| 2014 Q3 | 2.09 Million AUD | 11.85% |
| 2014 Q2 | 1.87 Million AUD | 0.0% |
| 2014 Q1 | 1.87 Million AUD | 15.36% |
| 2014 FY | 2.2 Million AUD | 32.2% |
| 2014 Q4 | 2.09 Million AUD | 0.0% |
| 2013 Q3 | 1.62 Million AUD | 0.0% |
| 2013 FY | 1.66 Million AUD | -63.33% |
| 2013 Q4 | 1.62 Million AUD | 0.0% |
| 2012 FY | 4.54 Million AUD | -50.06% |
| 2011 FY | 9.09 Million AUD | 20.12% |
| 2010 FY | 7.57 Million AUD | -5.31% |
| 2009 FY | 7.99 Million AUD | 13.15% |
| 2008 FY | 7.06 Million AUD | 1.7% |
| 2007 FY | 6.94 Million AUD | -2.29% |
| 2006 FY | 7.1 Million AUD | 23.33% |
| 2005 FY | 5.76 Million AUD | 454.05% |
| 2004 FY | 1.04 Million AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 10.86 Million USD | 79.729% |
| Skye Bioscience, Inc. | 13.54 Million USD | 83.74% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 94.087% |
| Nascent Biotech, Inc. | 2.22 Million USD | 1.213% |
| Qrons Inc. | 643.67 Thousand USD | -242.226% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 90.412% |
| CSL Limited | 3.44 Billion USD | 99.936% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 92.546% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 56.311% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -138.528% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 96.165% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -430.191% |
| Rebus Holdings, Inc. | 664 Thousand USD | -231.752% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -64.953% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -465.458% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 86.241% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 97.462% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 55.208% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -741.656% |
| SQZ Biotechnologies Company | 85.61 Million USD | 97.427% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 24.463% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -46.67% |
| Mesoblast Limited | 5.9 Million USD | 62.677% |
| Marizyme, Inc. | 19.23 Million USD | 88.551% |
| Genus plc | 147.7 Million USD | 98.509% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 74.909% |
| Pharming Group N.V. | 225.49 Million USD | 99.023% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -7.523% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -64.201% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 73.584% |
| ContraFect Corporation | 56.88 Million USD | 96.128% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 50.034% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -48.966% |
| IMV Inc. | 37.7 Million USD | 94.158% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 21.056% |
| MultiCell Technologies, Inc. | 567.42 USD | -388118.956% |
| ONE Bio Corp. | 6.44 Million USD | 65.815% |
| Accustem Sciences Inc. | 3.74 Million USD | 41.202% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 97.437% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -314.096% |
| Q BioMed Inc. | 3.43 Million USD | 35.901% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 91.087% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 16.163% |
| Biomind Labs Inc. | 994.18 Thousand USD | -121.572% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 97.782% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -25.184% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 67.21% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -18.154% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 8911.328% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -20.039% |
| GB Sciences, Inc. | 1.42 Million USD | -55.073% |
| Alpha Cognition Inc. | 9.7 Million USD | 77.303% |
| HST Global, Inc. | 140.9 Thousand USD | -1463.323% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -95.823% |
| Halberd Corporation | 74.84 Thousand USD | -2843.31% |
| Enzolytics Inc. | 2.17 Million USD | -1.07% |
| Agentix Corp. | 1.37 Million USD | -60.585% |
| Resverlogix Corp. | 12.71 Million USD | 82.671% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 39.66% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.856% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -110.999% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 8.404% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -39.477% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 35.306% |
| AVAX Technologies, Inc. | 7.31 Million USD | 69.867% |
| Zenith Capital Corp. | 8.94 Million USD | 75.368% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.733% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -12544.693% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 10.283% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1184.383% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -14.677% |
| Kadimastem Ltd | 2.41 Million USD | 8.6% |
| Helix BioMedix, Inc. | 1.97 Million USD | -11.704% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1113.782% |
| LadRx Corporation | 3.81 Million USD | 42.21% |
| Cell Source, Inc. | 4.32 Million USD | 49.072% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -138.528% |
| NovAccess Global Inc. | 2.46 Million USD | 10.699% |
| Affymax, Inc. | 39.38 Million USD | 94.407% |
| Itoco Inc. | 919.14 Thousand USD | -139.662% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 48.027% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -96.857% |
| Mobile Lads Corp. | 554.54 Thousand USD | -297.232% |
| CytoDyn Inc. | 18.05 Million USD | 87.801% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -8652.163% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -900.932% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -55.152% |
| SYBLEU INC | 160.87 Thousand USD | -1269.273% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -21.28% |
| International Stem Cell Corporation | 5.27 Million USD | 58.208% |
| Bioxytran, Inc. | 3.82 Million USD | 42.336% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -4084.552% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -10728.452% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 93.926% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -36.145% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -199.365% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 29.192% |
| Neutra Corp. | 243.82 Thousand USD | -803.463% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 87.381% |
| PureTech Health plc | 144.59 Million USD | 98.477% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 89.249% |
| IXICO plc | 4.7 Million USD | 53.201% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 74.959% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.129% |
| CSL Limited | 3.89 Billion USD | 99.943% |
| Cellectis S.A. | 97.32 Million USD | 97.737% |